Daiichi Sankyo (4568) advances on positive US FDA anti-cancer treatment approvals
Daiichi Sankyo Company (4568) shares advanced following positive reception to US Food and Drug Administration (FDA) approvals for its anti-cancer treatments. The stock is up 3.4%, trading at ¥2,738, an increase from its previous close of ¥2,650.
The share price rise stems from new FDA indications for ENHERTU in HER2-positive early breast cancer and Datopotamab deruxtecan (Datroway) for metastatic triple-negative breast cancer. These approvals are anticipated to generate milestone payments and significantly contribute to future growth within the oncology sector. While the company's full-year 2026 financial results, announced on 11 May, showed a decline in net profit and lower-than-expected earnings per share, sales increased, with oncology products, including ENHERTU, projected to drive growth for the 2026 fiscal year.
Analysts maintain a consensus "Strong Buy" rating on Daiichi Sankyo, with their average 12-month price target indicating substantial upside potential.
How Drug Approvals Boost Daiichi Sankyo's Growth Expectations
Daiichi Sankyo is a major Japanese pharmaceutical company engaged in the research, development, manufacturing, and sale of innovative medicines. The core of its business lies in creating treatments for cancer, infectious diseases, and other conditions, and providing these to patients and healthcare professionals worldwide. The company particularly focuses on developing new drugs in areas with high unmet medical needs, generating revenue through their sales.
Today, the specific factor that pushed up the company's share price was the US Food and Drug Administration (FDA)'s approval of new indications for its anti-cancer drugs. Specifically, the expanded indication for ENHERTU in HER2-positive early breast cancer and the approval of Datroway for metastatic triple-negative breast cancer were well received. These approvals create new sales opportunities and trigger milestone payments, significantly boosting expectations for future revenue growth in the oncology division. This comes even though the recently announced full-year 2026 results showed net profit and earnings per share falling below market forecasts, while sales increased, with the oncology division, including ENHERTU, expected to drive growth this period.
This regulatory approval has instilled confidence in the market regarding Daiichi Sankyo's growth strategy. The stock price rose 3.4% from yesterday's closing price of ¥2,650 and is currently trading at ¥2,738.
This is much like a restaurant developing a new menu item, and its recipe clearing strict food safety standards to receive sales approval. It is not just that the dish is complete, but the public guarantee of its quality and safety increases the expectation that more customers will confidently order the new item, significantly boosting the restaurant's sales and future reputation.
Daiichi Sankyo Company
Daiichi Sankyo Company, Limited (4568) is a Japanese healthcare firm specialising in pharmaceutical research, development, manufacturing, and sales globally. Its diverse product portfolio includes oncology treatments such as trastuzumab deruxtecan and anti-HER2 antibody drug conjugate, alongside therapies for pain, diabetes, epilepsy, and cardiovascular conditions. The company also produces vaccines for influenza, measles, rubella, and mumps. Beyond prescription drugs, Daiichi Sankyo offers a range of over-the-counter products including cold remedies, analgesics, skincare, and oral care. Additionally, it supplies pharmaceuticals for animals, cosmetics, medical equipment, and food products. The company collaborates with Guardant Health on companion diagnostics for advanced metastatic non-small cell lung cancer. Established in 1899, Daiichi Sankyo is headquartered in Tokyo, Japan.